<DOC>
	<DOCNO>NCT00264732</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety amolimogene , treatment patient high-grade cervical intraepithelial lesion uterine cervix .</brief_summary>
	<brief_title>A Study Amolimogene ( ZYC101a ) Patients With High Grade Cervical Intraepithelial Lesions Uterine Cervix</brief_title>
	<detailed_description>This double-blind study , neither patient doctor know treatment assign .</detailed_description>
	<mesh_term>Uterine Cervical Dysplasia</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<criteria>To consider enrollment , patient must : 1 . Have abnormal Pap smear ( atypical squamous cell undetermined significance [ ASCUS ] , atypical squamous cell , exclude high grade [ ASCH ] , low grade squamous intraepithelial lesion [ LSIL ] , high grade squamous intraepithelial lesion [ HSIL ] ) result within 6 month screen visit . 2 . Have colposcopically visible lesion suspect highgrade involve 75 % cervix . 3 . Have CIN 2/3 consensus pathology diagnosis tissue take colposcopicallydirected punch biopsy . 4 . Not evidence cervical carcinoma Pap smear biopsy positive endocervical curettage . 5 . Not atypical endometrial cell glandularcell atypia Pap smear biopsy . 6 . Have colposcopic visualization entire squamocolumnar junction entire lesion ( i.e . extend canal ) . 7 . Not concomitant cancer , history malignancy , include carcinoma cervix , except nonmelanoma skin cancer . 8 . Be willing sign Institutional Review Board ( IRB ) approve informed consent . Minors must consent parent legal guardian require local law regulation . 9 . Agree use 2 acceptable form contraception ( e.g. , doublemethod include least one barrier one hormonal method ) . 10 . Be capable comply protocol . 11 . Not illness would put patient undue risk participation trial would interfere require clinical observation . 12 . Not abnormalities hematological , renal , hepatic function determine clinical laboratory test . 13 . Not immunologic disorder immunodeficiency , lupus , chronic autoimmune disease . 14 . Not active systemic infection require treatment . 15 . Not ongoing systemic chronic steroid therapy immunosuppressive medication ( inhaler use treat asthma topical steroid permit ) . 16 . Not positive HIV antibody . 17 . Not pregnant lactating . 18 . Not plan use cervical cap diaphragm study . 19 . Not treated investigational agent within 30 day prior randomization trial . 20 . Not prior gene therapy . 21 . Not excisional ablative procedure perform cervix within one year enrollment . 22 . Be willing consent excisional procedure , LEEP coldknife cone procedure , indicate . Please note : There may additional inclusion/exclusion criterion . The study center determine patient meet criterion . If patient qualify trial , study personnel explain reason . If patient qualify , study personnel explain trial detail use IRBapproved informed consent , answer question . Patients decide wish participate .</criteria>
	<gender>Female</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>cervical lesion</keyword>
	<keyword>cervical dysplasia</keyword>
	<keyword>Human papilloma virus</keyword>
	<keyword>abnormal Pap</keyword>
	<keyword>High-grade cervical intraepithelial lesion ( CIN 2/3 )</keyword>
</DOC>